drugset / Trial / NCT03717038
Sym004 Versus TAS-102 in Patients With mCRC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 3, randomized, open-label, 2-arm trial designed to evaluate overall survival (OS) following treatment with Sym004, an investigational medicinal product (IMP), versus TAS-102 (trifluridine/tipiracil), a comparator (control) agent.
Timeline
- Start
- 2019-02
- Primary completion
- 2023-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Futuximab | Monoclonal antibody | — | — |
| Subject | Modotuximab | Monoclonal antibody | — | — |
| Comparator | Tipiracil | Small molecule | — | — |
| Comparator | Trifluridine | Small molecule | — | — |